187430@2x.png

Erlotinib clinical trials

Erlotinib is a selective, reversible tyrosine kinase inhibitor which binds with high affinity to the mutated EGFR receptor, thus preventing promotion of tumour cell survival and proliferation.1

page_3@2x.png

Please click below for more information on the key clinical trials that demonstrate
erlotinib's safety and efficacy profile in the first-line treatment of EGFR Mut+ NSCLC.

ENSURE phase III trial
(Asian patients)
EURTAC phase III trial
(European patients)
OPTIMAL phase III trial
(Chinese patients)